Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Jul 16, 2022 in Colorectal cancer | 0 comments

In a nutshell

This study compared the effectiveness and safety of immunotherapy versus standard treatment options in patients with metastatic colorectal cancer (mCRC). The data showed that immunotherapy tended to improve the survival outcomes in these patients.

Some background

Colorectal cancer (CRC) is one of the most common types of cancer worldwide. Some patients do not report symptoms with the initial tumor. These patients are often only diagnosed when the cancer has spread to other areas (metastatic CRC). The standard treatment for these patients is chemotherapy with targeted therapy or supportive care.

Immunotherapy uses the body’s own system to fight cancer. Tumor cells try to avoid death by switching off our immune system. They bind to proteins on the surface of the immune cells such as PD-1/PD-L1 or CTLA-4. Immune checkpoint inhibitors (ICIs) such as pembrolizumab (Keytruda), atezolizumab (Tencentriq), and ipilimumab (Yervoy) block these interactions and turn on the immune system to attack and kill the cancer cells. There are very few studies comparing the effectiveness and safety of immunotherapy versus standard treatment options in patients with mCRC.

Methods & findings

This study analyzed 5 studies and involved 1423 patients with mCRC. Patients were divided into 2 groups. Group 1 included patients who received immunotherapy. Group 2 included patients who received either chemotherapy with targeted therapy or supportive care.

Patients in group 1 were 5% more likely to survive without cancer worsening than patients in group 2. Patients in group 1 were 12% more likely to have a better overall survival than patients in group 2. 

The bottom line

This study concluded that immunotherapy tended to improve survival outcomes in patients with mCRC compared to standard therapies.

The fine print

This study analyzed small studies. The therapies used were very different. 

Published By :

Oncology letters

Date :

Apr 01, 2022

Original Title :

PD-1/PD-L1 blockade, a novel strategy for targeting metastatic colorectal cancer: A systematic review and meta-analysis of randomized trials.

click here to get personalized updates